Monoclonal Antibody Therapeutics 2009-2024 : Market Research Report

Monoclonal Antibody Therapeutics 2009-2024

Published by: Visiongain

Published: Jun. 8, 2009 - 205 Pages

1 Executive Summary
2 Introduction to Monoclonal Antibodies: 2.1 Antibodies; 2.2 Monoclonal Antibody Therapeutics
3 The Global Monoclonal Antibodies Market, 2009-2024: 3.1 Monoclonal Antibodies: Market Overview; 3.2 The Oncology Monoclonal Antibodies Market; 3.3 MabThera/Rituxan; 3.4 Avastin; 3.5 Herceptin; 3.6 Erbitux; 3.7 Other Oncology Monoclonal Antibodies; 3.8 The Autoimmune Disorder Monoclonal Antibodies Market; 3.9 Remicade; 3.10 Humira; 3.11 Novel Anti-TNF Monoclonal Antibodies; 3.12 MabThera/Rituxan for Autoimmune Disorders; 3.13 Xolair; 3.14 Tysabri; 3.15 Other Autoimmune Disorder Monoclonal Antibodies; 3.16 Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders); 3.17 Lucentis; 3.18 Synagis; 3.19 ReoPro
4 Monoclonal Antibody Country Markets: 4.1 Regional Overview; 4.2 The US Monoclonal Antibody Therapeutics Market; 4.3 European Monoclonal Antibody Therapeutics Market; 4.4 Monoclonal Antibodies in Emerging Markets
5 The Monoclonal Antibody Therapeutic Pipeline: 5.1 Late-Stage Oncology Pipeline: Additional and Expanded Indications; 5.2 Late-Stage Oncology Pipeline: Novel Entities; 5.3 Late-Stage Autoimmune Disorder Pipeline: Additional and Expanded Indications; 5.4 Late-Stage Autoimmune Disorder Pipeline: New Entities; 5.5 Other Monoclonal Antibodies Pipeline (Non-Oncology/Autoimmune Disorders); 5.6 Early Stage Pipeline: Antibody Fragments
6 Issues Affecting the Monoclonal Antibodies Market: 6.1 SWOT Chart for the Monoclonal Antibodies Industry; 6.2 Strengths; 6.3 Weaknesses; 6.4 Opportunities; 6.5 Threats
7 Interviews with Monoclonal Antibody Industry Key Opinion Leaders: 7.1 Dr Debbie Law, Chief Scientific Officer, and Eva-Lotta Allan, Chief Business Office, Ablynx; 7.2 Janice M. Reichert, PhD, Senior Research Fellow at Tufts University; 7.3 David Blakey, PhD, Chief Scientist, Cancer & Infection Research Area, AstraZeneca
8 Conclusions: 8.1 Monoclonal Antibodies Account for Over 30% of Biologic Drug Revenues; 8.2 Future Prospects for the Monoclonal Antibody Market; 8.3 The Monoclonal Antibody Pipeline; 8.4 Recent High Growth Rates Set to Continue to 2014; 8.5 Market Forecast, 2014-2024; 8.6 Expansion into New Markets; 8.7 Future Outlook
List of Tables: Table 2.1 Monoclonal Antibody Technology; Table 2.2 Modes of Action for Monoclonal Antibody Therapeutics; Table 2.3 Monoclonal Antibody Therapeutics Approved by US FDA, 1986-2003; Table 2.4 Monoclonal Antibody Therapeutics Approved by US FDA, 2003-2009; Table 3.1 Monoclonal Antibody Sales by Therapeutic Area, 2008; Table 3.2 Sales of Leading Monoclonal Antibodies, 2008; Table 3.3 Monoclonal Antibody Sales by Technology Type, 2008; Table 3.4 Sales of Monoclonal Antibodies by Antibody Type, 2008; Table 3.5 Sales of Monoclonal Antibodies by Marketing Company, 2008; Table 3.6 Monoclonal Antibody Therapeutic Market, Drivers & Restraints, 2009-2024; Table 3.7 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2014; Table 3.8 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2015-2024; Table 3.9 Sales of Leading Oncology Monoclonal Antibodies, 2008; Table 3.10 Sales by Technology Type, Oncology Monoclonal Antibodies, 2008; Table 3.11 Sales by Antibody Type, Oncology Monoclonal Antibodies, 2008; Table 3.12 Sales by Marketing Company, Oncology Monoclonal Antibodies, 2008; Table 3.13 Oncology Monoclonal Antibodies, Drivers & Restraints, 2009-2024; Table 3.14 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2009-2014; Table 3.15 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2015-2024; Table 3.16 MabThera/Rituxan Sales by Marketing Company, 2008; Table 3.17 MabThera/Rituxan Sales by Country, 2008; Table 3.18 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2014; Table 3.19 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2015-2024; Table 3.20 MabThera/Rituxan, Drivers & Restraints, 2009-2024; Table 3.21 Avastin Sales by Marketing Company, 2008; Table 3.22 Avastin Sales by Country, 2008; Table 3.23 Avastin, Drivers & Restraints, 2009-2024; Table 3.24 Herceptin Sales by Marketing Company, 2008; Table 3.25 Herceptin Sales by Country, 2008; Table 3.26 Herceptin, Drivers & Restraints, 2009-2024; Table 3.27 Erbitux Sales by Marketing Company, 2008; Table 3.28 Erbitux Sales by Country, 2008; Table 3.29 Erbitux, Drivers & Restraints, 2009-2024; Table 3.30 Major Nimotuzumab Markets, 2009; Table 3.31 Sales of Leading Autoimmune Disorder Monoclonal Antibodies, 2008; Table 3.32 Sales by Technology Type, Autoimmune Disorder Monoclonal Antibodies, 2008; Table 3.33 Sales by Antibody Type, Autoimmune Disorder Monoclonal Antibodies, 2008; Table 3.34 Sales by Marketing Company, Autoimmune Disorder Monoclonal Antibodies, 2008; Table 3.35 Autoimmune Disorder Monoclonal Antibodies, Drivers & Restraints, 2009-2024; Table 3.36 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014; Table 3.37 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024; Table 3.38 Remicade Sales by Marketing Company, 2008; Table 3.39 Remicade Sales by Country, 2008; Table 3.40 Remicade, Drivers & Restraints, 2009-2024; Table 3.41 Approved Indications for Humira in the US; Table 3.42 Humira Sales by Marketing Company, 2008; Table 3.43 Humira Sales by Country, 2008; Table 3.44 Humira, Drivers & Restraints, 2009-2024; Table 3.45 Cimzia, Drivers & Restraints, 2009-2024; Table 3.46 Simponi, Drivers & Restraints, 2009-2024; Table 3.47 MabThera/Rituxan (Autoimmune Indications), Xolair & Tysabri Sales Forecasts, 2009-2014; Table 3.48 MabThera/Rituxan (Autoimmune Indications), Xolair, & Tysabri Sales Forecasts, 2015-2024; Table 3.49 Tysabri Sales by Country, 2008; Table 3.50 Sales of Leading Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders), 2008; Table 3.51 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014; Table 3.52 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024; Table 3.53 Lucentis Sales by Marketing Company, 2008; Table 3.54 Lucentis Sales by Country, 2008; Table 3.55 Drivers and Restraints on Lucentis Revenues, 2009-2014; Table 3.56 Synagis Sales by Marketing Company, 2008; Table 3.57 Synagis Sales by Country, 2008; Table 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008; Table 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024; Table 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008; Table 4.4 Leading Ten US Monoclonal Antibodies, 2008; Table 5.1 Oncology Pipeline: Additional Indications for Avastin; Table 5.2 Oncology Pipeline: Additional Indications for Approved Drugs (Other than Avastin); Table 5.3 Oncology Pipeline: Selected New Entities in Phase III or Regulatory/Submission; Table 5.4 Oncology Pipeline: Selected New Entities in Phase II, Part 1; Table 5.5 Oncology Pipeline: Selected New Entities in Phase II, Part 2; Table 5.6 Autoimmune Disorders Pipeline: Additional Indications for Approved Drugs; Table 5.7 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 1; Table 5.8 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 2; Table 5.9 Autoimmune Disorder Pipeline: Selected New Entities in Phase II; Table 5.10 Pipeline for Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders); Table 5.11 Antibody Fragment Pipeline; Table 5.12 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 1; Table 5.13 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 2; Table 6.1 SWOT Chart for the Monoclonal Antibody Therapeutics Industry, 2009-2024; Table 6.2 Monoclonal Antibody Targets; Table 6.3 Expected Patent Expiries for Monoclonal Antibodies; Table 6.4 Biosimilar Monoclonal Antibodies in Development
List of Figures: Figure 2.1 Antibody Structure; Figure 3.1 Monoclonal Antibody Therapeutic Area Market Share, 2008; Figure 3.2 Leading Monoclonal Antibodies Market Share, 2008; Figure 3.3 Monoclonal Antibody Technology Type Market Share, 2008; Figure 3.4 Monoclonal Antibody Type Market Share, 2008; Figure 3.5 Monoclonal Antibody Marketing Company Market Share, 2008; Figure 3.6 Total Monoclonal Antibodies Sales Forecast, 2009-2024; Figure 3.7 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2024; Figure 3.8 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Market Share, 2009-2024; Figure 3.9 Leading Oncology Monoclonal Antibodies Market Share, 2008; Figure 3.10 Technology Type Market Share, Oncology Monoclonal Antibodies, 2008; Figure 3.11 Antibody Type Market Share, Oncology Monoclonal Antibodies, 2008; Figure 3.12 Marketing Company Market Share, Oncology Monoclonal Antibodies, 2008; Figure 3.13 Total Oncology Monoclonal Antibodies Sales Forecast, 2009-2024; Figure 3.14 MabThera/Rituxan, Avastin, Herceptin and Erbitux & Other Oncology Monoclonal Antibodies Market Share, 2009-2024; Figure 3.15 MabThera/Rituxan Marketing Company Market Share, 2008; Figure 3.16 MabThera/Rituxan Country Market Share, 2008; Figure 3.17 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2024; Figure 3.18 Avastin Marketing Company Market Share, 2008; Figure 3.19 Avastin Country Market Share, 2008; Figure 3.20 Avastin Sales Forecast, 2009-2024; Figure 3.21 Herceptin Marketing Company Market Share, 2008; Figure 3.22 Herceptin Country Market Share, 2008; Figure 3.23 Herceptin Sales Forecast, 2009-2024; Figure 3.24 Erbitux Marketing Company Market Share, 2008; Figure 3.25 Erbitux Sales Country Market Share, 2008; Figure 3.26 Erbitux Sales Forecast, 2009-2024; Figure 3.27 Leading Autoimmune Disorder Monoclonal Antibodies Market Share, 2008; Figure 3.28 Technology Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008; Figure 3.29 Antibody Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008; Figure 3.30 Marketing Company Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008; Figure 3.31 Total Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024; Figure 3.32 Remicade, Humira, Simponi, & Other Autoimmune Disorder Monoclonal Antibodies Market Share, 2009-2024; Figure 3.33 Remicade Marketing Company Market Share, 2008; Figure 3.34 Remicade Country Market Share, 2008; Figure 3.35 Remicade Sales Forecast, 2009-2024; Figure 3.36 Humira Marketing Company Market Share, 2008; Figure 3.37 Humira Country Market Share, 2008; Figure 3.38 Humira Sales Forecast, 2009-2024; Figure 3.39 Cimzia Sales Forecast, 2009-2024; Figure 3.40 Simponi Sales Forecast, 2009-2024; Figure 3.41 Xolair Sales Forecast, 2009-2024; Figure 3.42 Tysabri Country Market Share, 2008; Figure 3.43 Tysabri Sales Forecast, 2009-2024; Figure 3.44 Total Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024; Figure 3.45 Lucentis Marketing Company Market Share, 2008; Figure 3.46 Lucentis Country Market Share, 2008; Figure 3.47 Lucentis Sales Forecast, 2009-2024; Figure 3.48 Synagis Marketing Company Market Share, 2008; Figure 3.49 Synagis Country Market Share, 2008; Figure 3.50 Synagis/Motavizumab Sales Forecast, 2009-2024; Figure 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008; Figure 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024; Figure 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008; Figure 4.4 Leading Ten US Monoclonal Antibodies, 2008; Figure 4.5 US Monoclonal Antibodies Sales Forecast, 2009-2024; Figure 5.1 Antibody Fragment Types; Figure 8.1 World Monoclonal Antibody Therapeutics Market Forecast, 2009-2024; Abbott; Abgenix (acquired by Amgen, 2006); Ablynx; Actinium; Affimed Therapeutics; Alcon (Nestlé); Alexion; Amgen; Arana Therapeutics; AstraZeneca; Bayer; Biocon; Biogen (merged with IDEC in 2003 to form Biogen Idec); Biogen Idec; BioTech Pharma [Chinese/Cuban joint venture]; Biotest; Boehringer Ingelheim; Bradmer; Bristol-Myers Squibb; Cambridge Antibody Technology (CAT) (acquired by AstraZeneca); Cell Therapeutics; Celltech (acquired by UCB, 2004); Center of Molecular Immunology [Cuba]; Centocor (acquired by Johnson & Johnson, 1999); Cephalon; Ception Therapeutics; Chugai (majority-owned by Roche); Committee for Medicinal Products for Human Use (CHMP) (part of EMEA); Corixa (acquired by GSK, 2005); Daiichi-Sankyo; Dainippon Sumitomo; Domantis (acquired by GSK, 2007); Dr. Reddy's Laboratories; Eisai; Elan; Eli Lilly; ESBATech; Esteve; Eurofarma [Brazil]; European Medicines Agency (EMEA); Facet Biotech (formerly part of PDL BioPharma); Food and Drug Administration (FDA) [US]; Fresenius; Genentech (acquired by Roche in March 2009); Genmab; Genzyme; GSK (GlaxoSmithKline); GTC Biotherapeutics; Health Canada; Human Genome Sciences; IDEC (merged with Biogen in 2003 to form Biogen Idec); Ilex Oncology (acquired by Genzyme, 2004); ImClone (acquired by Eli Lilly, November 2008); ImmunoGen; Immunomedics; Implicit Bioscience; Johnson & Johnson; Kyowa Hakko Kirin; Laboratorio Elea [Argentina]; LFB Biotechnologies; Ludwig Institute for Cancer Research; MacroGenics; Medarex; MedImmune (acquired by AstraZeneca, 2007); Menarini; Merck & Co.; Merck KGaA; Micromet; Millennium (acquired by Takeda, 2008); Ministry of Health, Labour and Welfare (MHLW) [Japan]; Mitsubishi Tanabe; Morphotek (acquired by Eisai, 2007); National Cancer Institute (NCI, part of NIH) [US]; National Eye Institute (NEI, part of NIH) [US]; National Institutes of Health (NIH) [US]; NeuTec (acquired by Novartis, 2006); Novartis; Nycomed; Oncoscience; Onyx; Osaka University; Otsuka; PDL BioPharma; Peregrine; Pfizer; Pierre Fabre; Progenics; Ranbaxy; Rinat (acquired by Pfizer, 2006); Roche; Roche Group (Roche, Genentech & Chugai); Sanofi-Aventis; Schering-Plough; Seattle Genetics; Shanghai Medipharm Biotech (Medipharm); Shantha Biotechnics; Spectrum; State Food and Drug Administration (SFDA) [China]; Takeda; Tanox (acquired by Genentech in 2007; Tolerx; Trion; UCB; University of Massachusetts Medical School; Viventia; Wilex; Wyeth; Xoma; YM Biosciences; Zenotech; Zenyaku Kogyo

Abstract

Monoclonal antibodies achieved total sales of nearly $32bn in 2008 and have grown rapidly to command over 30% of the global biologic drug market. We expect significant opportunities for further commercial growth from 2009 to 2024, as shown in our new report, Monoclonal Antibody Therapeutics 2009-2024. New technologies will be an important growth driver. Intensive R&D activity is producing an exciting antibody pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. Furthermore, monoclonal antibodies already on the market have scope for additional development. In particular, visiongain foresees the application of monoclonal antibodies in new therapeutic areas, outside the currently-established fields.

At the same time, challenges and changes lie ahead. Increased competition for antibody targets and patient populations, pricing pressures from governments and other healthcare payers, patent expiry for high-revenue monoclonal antibodies and the spectre of biosimilar monoclonal antibodies will come to the fore during the period 2009 to 2024.

What will be the characteristics of drugs that will succeed Avastin and Remicade, becoming the blockbusters of the future? What are the potential applications and prospects for antibody fragments? Which pipeline drugs are the ones to watch? Our completely updated report - packed with 140 tables and figures - will show you the outlook for this dynamic sector of the pharmaceutical market.

Comprehensive analysis of the monoclonal antibody therapeutics market

Monoclonal Antibody Therapeutics 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are also three detailed interviews with authorities on the sector in this 200+ page report. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy this report

By ordering Monoclonal Antibody Therapeutics 2009-2024 you will:

Find out the market prognosis for the global monoclonal antibody therapeutics market and for the relevant markets in oncology, autoimmune disorders and other therapeutic areas from 2009 to 2024
Receive comprehensive market forecasts and competitive analyses for leading monoclonal antibodies, including Rituximab, Avastin, Herceptin, Erbitux, Remicade, Humira, Xolair, Tysabri, Lucentis and Synagis, and for potential blockbusters of the future
Read expert views from key-opinion leaders in the monoclonal antibody field, with full interview transcripts provided
Examine strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the industry, including the prospects for biosimilar monoclonal antibodies
Discover market forecasts for the leading monoclonal antibody country markets and for the emerging markets of China and India
Analyse the monoclonal antibody therapeutics pipeline, especially for late-stage candidates, including the prospects for antibody fragments and antibody-drug conjugates.

You can obtain this report today

Monoclonal Antibody Therapeutics 2009-2024 will provide your company with the essential information it needs to understand this dynamic and rapidly-expanding sector. This report provides a comprehensive analysis of the global monoclonal antibody therapeutics market, giving a balanced view of future technological and commercial prospects there. Do you want to know more about this important market? You can stay ahead by ordering this report today.

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Monoclonal Antibody Therapeutics 2009-2024

Table of Contents

Abstract